Dinya DNA files to raise $4.3M for on-demand DNA synthesis

What's the deal? Dinya DNADealroom has a profile for this one. Try Dealroom → has filed a notice with the U.S. Securities and Exchange Commission to raise up to $4,297,104 in new funding, of which roughly $3.77M had already been sold at the time of the filing. The company makes complex, custom double-stranded DNA sequences on demand for research and development, positioning its next-gen exponential synthesis platform around speed and cost. President Benjamin Lerman is listed as the contact on the filing.

Why now? The SEC filing signals the round is already underway: companies must file the notice within 15 days of the first sale, meaning at least one investor has committed capital. The first sale is dated June 2026.

The signal: The filing is a Regulation D exempt offering, a common route for early-stage companies raising privately without registering the securities. It offers an early public marker of a synthetic-biology startup building tools for the labs it serves.

Read more: Intelligence360

Image credit: USDAgov